• 제목/요약/키워드: atovaquone

검색결과 6건 처리시간 0.015초

Babesia gibsoni 자연 감염개에서의 Atovaquone/Proguanil 합제와 Azithromycin 병용투여에 따른 치료효과 (Therapeutic Effects of Atovaquone/Proguanil in Combination with Azithromycin in Dogs Naturally Infected with Babesia gibsoni)

  • 이대근;김윤기;윤영민;이경갑
    • 한국임상수의학회지
    • /
    • 제33권1호
    • /
    • pp.16-20
    • /
    • 2016
  • This study was performed to estimate the clinical use of combination therapy with atovaquone/proguanil and azithromycin as a effective treatment in dogs infected with Babesia gibsoni. Eight mixed-breed dogs that were infected naturally with B. gibsoni were used in this study. Four dogs (No. 1-4) as experimental group received atovaquone/proguanil and azithromycin therapy. As for the other four dogs as the control group (No. 5-8) were administered diminazene aceturate and tetracycline/clindamycin. All the dogs in this study showed mild to severe anemia and thrombocytopenia. After initiating the treatment B. gibsoni in blood smears disappeared. PCR analysis of the experimental group showed negative results during the observation period, but more than one dog from the control groups showed continuous positive results. Atovaquone/proguanil and azithromycin combination therapy can significantly lower the B. gibsoni parasitemia levels and the results suggested that this combination therapy should be a new protocol for an effective treatment in dogs infected with B. gibsoni.

Successful Management of Immune-Mediated Hemolytic Anemia Secondary to Infection with Cytauxzoon felis and Feline Immunodeficiency Virus

  • Choi, Hyeong-Il;Kim, Joonyong;Han, Jae-Ik;Kim, Ha-Jung
    • 한국임상수의학회지
    • /
    • 제37권4호
    • /
    • pp.223-226
    • /
    • 2020
  • Cytauxzoonosis is caused by Cytauxzoon felis (C. felis) in wild and domestic cats. However, cytauxzoonosis is uncommon in Asia. Additionally, clinical reports of C. felis infection along with associated complications are rare. A seven-year-old neutered male Maine Coon cat was presented with acute dyspnea and lethargy despite the absence of a history of overseas travel. Mild regenerative anemia and autoagglutination were detected in hematological investigations. The parasitic and viral PCR assays revealed infection with C. felis and feline immunodeficiency virus (FIV). Thoracic radiographs showed pleural effusion with secondary bacterial infection. Ultimately, a diagnosis of infection-induced secondary immune-mediated hemolytic anemia (IMHA) and pyothorax was established. The cat was treated with a combination of atovaquone, prednisolone, and cyclosporine over 6 months and the final treatment was completed 8 months after initiation of therapy. This is the first report of its kind demonstrating successful management of feline IMHA and fatal pyothorax induced by FIV and C. felis in South Korea.

Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum

  • Ha, Young Ran;Hwang, Bae-Geun;Hong, Yeonchul;Yang, Hye-Won;Lee, Sang Joon
    • Parasites, Hosts and Diseases
    • /
    • 제53권4호
    • /
    • pp.421-430
    • /
    • 2015
  • The parasite Plasmodium falciparum causes severe malaria and is the most dangerous to humans. However, it exhibits resistance to their drugs. Farnesyltransferase has been identified in pathogenic protozoa of the genera Plasmodium and the target of farnesyltransferase includes Ras family. Therefore, the inhibition of farnesyltransferase has been suggested as a new strategy for the treatment of malaria. However, the exact functional mechanism of this agent is still unknown. In addition, the effect of farnesyltransferase inhibitor (FTIs) on mitochondrial level of malaria parasites is not fully understood. In this study, therefore, the effect of a FTI R115777 on the function of mitochondria of P. falciparum was investigated experimentally. As a result, FTI R115777 was found to suppress the infection rate of malaria parasites under in vitro condition. It also reduces the copy number of mtDNA-encoded cytochrome c oxidase III. In addition, the mitochondrial membrane potential (${\Delta}{\Psi}m$) and the green fluorescence intensity of MitoTracker were decreased by FTI R115777. Chloroquine and atovaquone were measured by the mtDNA copy number as mitochondrial non-specific or specific inhibitor, respectively. Chloroquine did not affect the copy number of mtDNA-encoded cytochrome c oxidase III, while atovaquone induced to change the mtDNA copy number. These results suggest that FTI R115777 has strong influence on the mitochondrial function of P. falciparum. It may have therapeutic potential for malaria by targeting the mitochondria of parasites.

Antimalarial Effects of Areca catechu L.

  • Jiang, Jing-Hua;Jung, Suk-Yul;Kim, Youn-Chul;Shin, Sae-Ron;Yu, Seung-Taek;Park, Hyun
    • 동의생리병리학회지
    • /
    • 제23권2호
    • /
    • pp.494-498
    • /
    • 2009
  • The emergence and spread of drug-resistant malaria parasites is a serious public health problem in the tropical world. Useful antimalarial drugs such as chloroquine have resistance in the world now. Moreover, other antimalarialdrugs such as mefloquine, halofantrine, atovaquone, proguanil, artemether and lumefantrine retain efficacy but have limitations, one of which is their high cost. New antimalarial drugs are clearly needed now. Cytotoxicity assay and susceptibility assay were performed for the selectivity of herb extracts in vitro. On the basis of high selectivity, 4-day suppressive test and survival test were progressed in Plasmodium berghei-infected mice. The selectivity of Areca catechu L. (ACL) and butanol extract of ACL (ACL-BuOH extract) were 3.4 and 3.0 in vitro, respectively. Moreover in vivo, 4-day suppressive test showed 39.1 % inhibition effect after treated with 150 mg/kg/day ACL-BuOH to P. berghei-infected mice. Survival test also showed 60% survival rate with ACL-BuOH-treated group while all other group mice died. In this study, ACL and ACL-BuOH were investigated for antimalarial activity in vitro and in vivo and they showed a potent antimalarial activity. In particular,ACL-BuOH could specifically lead higher survival rate of mice in vivo. Therefore ACL-BuOH would be a candidate of antimalarial drugs.

Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein

  • Kim, Jinsoo;Hwang, Seok Young;Kim, Dongbum;Kim, Minyoung;Baek, Kyeongbin;Kang, Mijeong;An, Seungchan;Gong, Junpyo;Park, Sangkyu;Kandeel, Mahmoud;Lee, Younghee;Noh, Minsoo;Kwon, Hyung-Joo
    • Biomolecules & Therapeutics
    • /
    • 제30권5호
    • /
    • pp.427-434
    • /
    • 2022
  • The drug repurposing strategy has been applied to the development of emergency COVID-19 therapeutic medicines. Current drug repurposing approaches have been directed against RNA polymerases and viral proteases. Recently, we found that the inhibition of the interaction between the SARS-CoV-2 structural nucleocapsid (N) and spike (S) proteins decreased viral replication. In this study, drug repurposing candidates were screened by in silico molecular docking simulation with the SARS-CoV-2 structural N protein. In the ChEMBL database, 1994 FDA-approved drugs were selected for the in silico virtual screening against the N terminal domain (NTD) of the SARS-CoV-2 N protein. The tyrosine 109 residue in the NTD of the N protein was used as the center of the ligand binding grid for the docking simulation. In plaque forming assays performed with SARS-CoV-2 infected Vero E6 cells, atovaquone, abiraterone acetate, and digoxin exhibited a tendency to reduce the size of the viral plagues without affecting the plaque numbers. Abiraterone acetate significantly decreased the accumulation of viral particles in the cell culture supernatants in a concentration-dependent manner. In addition, abiraterone acetate significantly decreased the production of N protein and S protein in the SARS-CoV-2-infected Vero E6 cells. In conclusion, abiraterone acetate has therapeutic potential to inhibit the viral replication of SARS-CoV-2.

An Imported Case of Severe Falciparum Malaria with Prolonged Hemolytic Anemia Clinically Mimicking a Coinfection with Babesiosis

  • Na, Young Ju;Chai, Jong-Yil;Jung, Bong-Kwang;Lee, Hyun Jung;Song, Ji Young;Je, Ji Hye;Seo, Ji Hye;Park, Sung Hun;Choi, Ji Seon;Kim, Min Ja
    • Parasites, Hosts and Diseases
    • /
    • 제52권6호
    • /
    • pp.667-672
    • /
    • 2014
  • While imported falciparum malaria has been increasingly reported in recent years in Korea, clinicians have difficulties in making a clinical diagnosis as well as in having accessibility to effective anti-malarial agents. Here we describe an unusual case of imported falciparum malaria with severe hemolytic anemia lasting over 2 weeks, clinically mimicking a coinfection with babesiosis. A 48-year old Korean man was diagnosed with severe falciparum malaria in France after traveling to the Republic of Benin, West Africa. He received a 1-day course of intravenous artesunate and a 7-day course of Malarone (atovaquone/proguanil) with supportive hemodialysis. Coming back to Korea 5 days after discharge, he was readmitted due to recurrent fever, and further treated with Malarone for 3 days. Both the peripheral blood smears and PCR test were positive for Plasmodium falciparum. However, he had prolonged severe hemolytic anemia (Hb 5.6 g/dl). Therefore, 10 days after the hospitalization, Babesia was considered to be potentially coinfected. A 7-day course of Malarone and azithromycin was empirically started. He became afebrile within 3 days of this babesiosis treatment, and hemolytic anemia profiles began to improve at the completion of the treatment. He has remained stable since his discharge. Unexpectedly, the PCR assays failed to detect DNA of Babesia spp. from blood. In addition, during the retrospective review of the case, the artesunate-induced delayed hemolytic anemia was considered as an alternative cause of the unexplained hemolytic anemia.